ResMed Takes Action to Enforce Patents

                    ResMed Takes Action to Enforce Patents

Suit Filed against APEX Medical Corp. for Patent Infringement on Devices and
Masks

PR Newswire

SAN DIEGO, March 28, 2013

SAN DIEGO, March 28, 2013 /PRNewswire/ --ResMed, an innovator and pioneer in
developing products for the treatment of sleep-disordered breathing and
respiratory conditions, has filed parallel legal actions in the International
Trade Commission (ITC) and in U.S. federal court to stop the infringement of
ResMed patents.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

ResMed filed the actions against Taiwanese manufacturer APEX Medical and its
U.S. distributor, Medical Depot, Inc., doing business as Drive Medical Design
and Manufacturing. ResMed alleges that multiple ResMed patents are infringed
by several APEX products, including:

  oThe APEX WiZARD 210 and WiZARD 220 masks
  oThe identical Freedom 210 and Freedom 220 masks made by APEX and sold by
    Medical Depot
  oThe APEX iCH and XT Fit flow generators

ResMed is asking the ITC to stop the importation and sales of these products
in the United States, and it is asking the U.S. federal court to stop the
infringement and award damages against the defendants.

"For more than two decades, ResMed has generated significant advances in
innovative products for sleep-disordered breathing therapy," said ResMed
global general counsel and chief administrative officer David Pendarvis. "We
invest over a hundred million dollars in research and development each year to
fuel these advances and other companies should not be allowed to infringe
ResMed's intellectual property by using our technology."

About ResMed:
ResMed is a global leader in the development, manufacturing and marketing of
medical products for the diagnosis, treatment and management of respiratory
disorders, with a focus on sleep-disordered breathing. The company is
dedicated to developing innovative products to improve the lives of those who
suffer from these conditions and to increasing awareness among patients and
healthcare professionals of the potentially serious health consequences of
untreated sleep-disordered breathing. For more information on ResMed, visit
www.resmed.com.

Contacts:
For News Media                         For the Finance and Investor Community
Gretchen Griswold                      Constance Bienfait
Director, Global Corporate              Director, Investor Relations
Communications
O: 858-836-6789                        O: 858-836-5971
news@resmed.com                         constance.bienfait@resmed.com



SOURCE ResMed Inc.

Website: http://www.resmed.com
 
Press spacebar to pause and continue. Press esc to stop.